<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for IMS Health]]></title>
<description><![CDATA[Watch breaking news videos and read news updates about IMS Health on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=322956"/>
<item>
<title><![CDATA[FDA Bans Generic Oxycontin in Bid to Stop Abuse]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2013/04/17/fda-bans-generic-oxycontin-in-bid-to-stop-abuse/?]]></link>
<guid>http://www.foxbusiness.com/markets/2013/04/17/fda-bans-generic-oxycontin-in-bid-to-stop-abuse/</guid>
<pubDate><![CDATA[Wed, 17 Apr 2013 10:02:00 EDT]]></pubDate>
<description><![CDATA[Regulators banned generic versions of the narcotic OxyContin that could be abused via injection and snorting.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/investing/fdaBuilding.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Sanofi: U.S. Probes Disclosures to FDA About Patient Response to Plavix]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/03/08/sanofi-us-probes-disclosures-to-fda-about-patient-response-to-plavix/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/03/08/sanofi-us-probes-disclosures-to-fda-about-patient-response-to-plavix/</guid>
<pubDate><![CDATA[Fri, 08 Mar 2013 11:08:57 EST]]></pubDate>
<description><![CDATA[The U.S. Justice Department is investigating disclosures to the Food and Drug Administration about the variability in patient responses to the blood-thinning drug Plavix, according to Sanofi (SNY), one of the drug's co-marketers.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Pfizer Plans More Alliances in China]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/02/25/pfizer-plans-more-alliances-in-china/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/02/25/pfizer-plans-more-alliances-in-china/</guid>
<pubDate><![CDATA[Mon, 25 Feb 2013 07:55:04 EST]]></pubDate>
<description><![CDATA[New York-based Pfizer Inc., the world's largest drug company, plans to forge more alliances in China as pharmaceutical companies combat shrinking margins in one of the world's fastest-growing healthcare markets.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy Resumes Generic Lipitor Production for U.S.]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/02/22/ranbaxy-resumes-generic-lipitor-production-for-us/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/02/22/ranbaxy-resumes-generic-lipitor-production-for-us/</guid>
<pubDate><![CDATA[Fri, 22 Feb 2013 12:05:04 EST]]></pubDate>
<description><![CDATA[Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Bristol-Myers to Sell Brands in Brazil, Mexico]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/01/31/bristol-myers-to-sell-brands-in-brazil-mexico/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/01/31/bristol-myers-to-sell-brands-in-brazil-mexico/</guid>
<pubDate><![CDATA[Thu, 31 Jan 2013 21:06:08 EST]]></pubDate>
<description><![CDATA[Bristol-Myers Squibb Co. (BMY) is seeking a buyer for a collection of brands in Mexico and Brazil that could fetch as much as $750 million, according to people familiar with the matter, a deal that would highlight the strong demand from corporate acquirers for consumer health assets around the world.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Why One Drug Costs $295K a Year]]></title>
<link><![CDATA[http://www.foxbusiness.com/personal-finance/2013/01/24/why-one-drug-costs-25k-year/?]]></link>
<guid>http://www.foxbusiness.com/personal-finance/2013/01/24/why-one-drug-costs-25k-year/</guid>
<pubDate><![CDATA[Thu, 24 Jan 2013 11:45:55 EST]]></pubDate>
<description><![CDATA[The market for high-priced drugs meant to treat rare diseases is growing at a faster rate than the overall drug market. But even excluding these Rolls Royce drugs for uncommon diseases, brand-name pharmaceutical prices have risen faster than inflation.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/medicine_pills_health_care.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[FDA Requires Lower Doses for Certain Insomnia Drugs]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/01/10/fda-requires-lower-doses-for-certain-insomnia-drugs/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/01/10/fda-requires-lower-doses-for-certain-insomnia-drugs/</guid>
<pubDate><![CDATA[Thu, 10 Jan 2013 14:05:07 EST]]></pubDate>
<description><![CDATA[The Food and Drug Administration is requiring the makers of certain sleep-inducing drugs, including Ambien, to lower doses of the medicines because they have been shown to impair activities--such as driving--the morning after the drugs have been taken.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Report: Brand-Name Drug Prices Rise, But Generics Get Cheaper]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/11/28/report-brand-name-drug-prices-rise-but-generics-get-cheaper/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/11/28/report-brand-name-drug-prices-rise-but-generics-get-cheaper/</guid>
<pubDate><![CDATA[Wed, 28 Nov 2012 15:20:30 EST]]></pubDate>
<description><![CDATA[Prices for more popular brand-name prescription drugs have surged over the last year, although falling prices for generics have restrained overall U.S. spending on medicine, pharmacy-benefit manager Express Scripts Holding Co. (ESRX) said in a new report Wednesday.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[U.S. finds no wrongdoing in Yasmin patent settlement]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/10/02/us-finds-no-wrongdoing-in-yasmin-patent-settlement/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/10/02/us-finds-no-wrongdoing-in-yasmin-patent-settlement/</guid>
<pubDate><![CDATA[Tue, 02 Oct 2012 16:07:33 EDT]]></pubDate>
<description><![CDATA[U.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Roche to Showcase Personalized Medicine, Mid-Stage Pipeline]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/08/31/roche-to-showcase-personalized-medicine-mid-stage-pipeline/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/08/31/roche-to-showcase-personalized-medicine-mid-stage-pipeline/</guid>
<pubDate><![CDATA[Fri, 31 Aug 2012 10:49:50 EDT]]></pubDate>
<description><![CDATA[Roche Holding AG (ROG.VX) will tell investors attending a research-and-development presentation in London next week how it expects to grow by making increased use of its diagnostics unit to develop targeted medicines.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Lupin Launches Copy Of Geodon Schizophrenia Drug In US]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/03/04/lupin-launches-copy-geodon-schizophrenia-drug-in-us/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/03/04/lupin-launches-copy-geodon-schizophrenia-drug-in-us/</guid>
<pubDate><![CDATA[Sun, 04 Mar 2012 23:50:24 EST]]></pubDate>
<description><![CDATA[Lupin Ltd. (500257.BY) said Monday a unit has launched ziprasidone hydrochloride, a generic version of Pfizer Inc.'s (PFE) Geodon capsules for treating schizophrenia, in the U.S. after getting final approval from the country's drug regulator.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[FDA Cautions Statin Users on Side Effects]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/02/28/fda-cautions-statin-users-on-side-effects/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/02/28/fda-cautions-statin-users-on-side-effects/</guid>
<pubDate><![CDATA[Tue, 28 Feb 2012 17:30:57 EST]]></pubDate>
<description><![CDATA[Health regulators will add warnings to labels of widely used cholesterol-lowering drugs to indicate they may raise blood sugar and could cause memory loss.]]></description>
<media:thumbnail>http://www.foxbusiness.com/static/managed/img/fb2/personal-finance/medicine_pills_health_care.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Lupin Settles Patent Dispute Over Glumetza Diabetes Treatment]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/02/23/lupin-settles-patent-dispute-over-glumetza-diabetes-treatment/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/02/23/lupin-settles-patent-dispute-over-glumetza-diabetes-treatment/</guid>
<pubDate><![CDATA[Thu, 23 Feb 2012 02:35:07 EST]]></pubDate>
<description><![CDATA[Indian generic drug maker Lupin Ltd. (500257.BY) Thursday said it has settled a patent infringement litigation with Santarus Inc. (SNTS) and DepoMed Inc. (DEPO) over the Glumetza extended-release tablets for diabetes treatment.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Benefit Manager's Lipitor Move Highlights Pressure On Pfizer]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/27/benefit-managers-lipitor-move-highlights-pressure-on-pfizer/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/27/benefit-managers-lipitor-move-highlights-pressure-on-pfizer/</guid>
<pubDate><![CDATA[Fri, 27 Jan 2012 18:01:15 EST]]></pubDate>
<description><![CDATA[Pharmacy-benefit manager Express Scripts Inc. (ESRX) will soon make an adjustment that raises out-of-pocket costs for some customers filling prescriptions of Pfizer Inc.'s (PFE) cholesterol-lowering drug Lipitor, underscoring the drug maker's challenge of keeping sales high in the face of generic competition.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Diabetes 'Massive Challenge" as Cases Hit 366 Million]]></title>
<link><![CDATA[http://www.foxbusiness.com/personal-finance/2011/09/13/diabetes-massive-challenge-as-cases-hit-366-mln/?]]></link>
<guid>http://www.foxbusiness.com/personal-finance/2011/09/13/diabetes-massive-challenge-as-cases-hit-366-mln/</guid>
<pubDate><![CDATA[Tue, 13 Sep 2011 09:46:40 EDT]]></pubDate>
<description><![CDATA[The number of people living with diabetes has soared to 366 million, and the disease kills one person every seven seconds, posing a "massive challenge" to healthcare systems worldwide.]]></description>
<media:thumbnail>http://www.foxbusiness.com/static/managed/img/Nurse-Doctor-Care-Patient-Health-Care.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Branded Drug Prices Soar as Generic Pressure Rises]]></title>
<link><![CDATA[http://www.foxbusiness.com/personal-finance/2011/03/28/branded-drug-prices-soar-generic-pressure-rises/?]]></link>
<guid>http://www.foxbusiness.com/personal-finance/2011/03/28/branded-drug-prices-soar-generic-pressure-rises/</guid>
<pubDate><![CDATA[Mon, 28 Mar 2011 08:28:07 EDT]]></pubDate>
<description><![CDATA[New data shows prices for the 15 best-selling drugs rose by much higher rates in 2010 than they did in each of the last five years.]]></description>
<media:thumbnail>http://www.foxbusiness.com/static/managed/img/medicine_pills_health_care.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Bayer Pharma Teams Up With Cadila To Gain Footing In India]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2011/01/28/bayer-pharma-teams-cadila-gain-footing-india/?]]></link>
<guid>http://www.foxbusiness.com/markets/2011/01/28/bayer-pharma-teams-cadila-gain-footing-india/</guid>
<pubDate><![CDATA[Fri, 28 Jan 2011 10:48:37 EST]]></pubDate>
<description><![CDATA[MUMBAI -(Dow Jones)- Moving to fill a yawning gap in its emerging market strategy, German conglomerate Bayer AG (BAYN.XE) Friday said it formed a joint venture with India's Cadila Healthcare Ltd. (532321.BY) to sell health products there to an increasingly affluent middle class, focusing on women's health, metabolic disorders, heart disease, diabetes, cancer as well as diagnostic imaging devices.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Glenmark: Unit Gets FDA OK To Sell Generic Malaria Drug]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2011/01/19/glenmark-unit-gets-fda-ok-sell-generic-malaria-drug/?]]></link>
<guid>http://www.foxbusiness.com/markets/2011/01/19/glenmark-unit-gets-fda-ok-sell-generic-malaria-drug/</guid>
<pubDate><![CDATA[Wed, 19 Jan 2011 03:16:22 EST]]></pubDate>
<description><![CDATA[BANGALORE -(Dow Jones)- Glenmark Pharmaceuticals Ltd. (532296.BY) Wednesday said its generic drugs unit has received final approval from the U.S. Food and Drug Administration to sell a generic version of GlaxoSmithKline PLC's (GSK) malaria drug Malarone.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Lupin: Unit Gets FDA OK To Sell Generic Osteoarthritis Drug]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2011/01/14/lupin-unit-gets-fda-ok-sell-generic-osteoarthritis-drug/?]]></link>
<guid>http://www.foxbusiness.com/markets/2011/01/14/lupin-unit-gets-fda-ok-sell-generic-osteoarthritis-drug/</guid>
<pubDate><![CDATA[Fri, 14 Jan 2011 05:01:15 EST]]></pubDate>
<description><![CDATA[BANGALORE -(Dow Jones)- Lupin Ltd. (500257.BY) Friday said its U.S unit has received final approval from the U.S. Food and Drug Administration to sell its generic version of nabumetone tablets--in 500 milligram and 750 mg strengths--used for the treatment of osteoarthritis and rheumatoid arthritis.]]></description>
<media:thumbnail/>
</item>
</channel>
</rss>
